KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Current Deferred Revenue (2016 - 2025)

Arbutus Biopharma's Current Deferred Revenue history spans 12 years, with the latest figure at $6.8 million for Q1 2025.

  • For Q1 2025, Current Deferred Revenue fell 41.47% year-over-year to $6.8 million; the TTM value through Mar 2025 reached $6.8 million, down 41.47%, while the annual FY2024 figure was $7.6 million, 35.79% down from the prior year.
  • Current Deferred Revenue for Q1 2025 was $6.8 million at Arbutus Biopharma, down from $7.6 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $16.5 million in Q4 2022 and bottomed at $6.8 million in Q1 2025.
  • The 4-year median for Current Deferred Revenue is $11.7 million (2023), against an average of $11.9 million.
  • The largest annual shift saw Current Deferred Revenue fell 9.87% in 2024 before it tumbled 41.47% in 2025.
  • A 4-year view of Current Deferred Revenue shows it stood at $16.5 million in 2022, then dropped by 28.35% to $11.8 million in 2023, then plummeted by 35.79% to $7.6 million in 2024, then fell by 10.73% to $6.8 million in 2025.
  • Per Business Quant, the three most recent readings for ABUS's Current Deferred Revenue are $6.8 million (Q1 2025), $7.6 million (Q4 2024), and $10.9 million (Q3 2024).